4-Tert-butyl-1-(prop-2-ynyl)piperidine | 81613-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Tert-butyl-1-(prop-2-ynyl)piperidine
• 英文别名: 4-tert-butyl-1-prop-2-ynylpiperidine
• CAS: 81613-62-9
• 化学式: C₁₂H₂₁N
• 分子量: 179.3
• InChiKey: MJIAWJINANGQPX-UHFFFAOYSA-N

物化性质

• 沸点：
  224.3±23.0 °C(Predicted)
• 密度：
  0.889±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3,5-双(三氟甲基)碘苯 、 4-Tert-butyl-1-(prop-2-ynyl)piperidine 生成 氟鼠啶
  参考文献：
  名称：

  LEPTWICK, A. P.;PARNELL, E. W.

  摘要：

  DOI：
• 作为产物：
  描述：

  4-叔丁基哌啶 、 3-溴丙炔 生成 4-Tert-butyl-1-(prop-2-ynyl)piperidine
  参考文献：
  名称：

  LEPTWICK, A. P.;PARNELL, E. W.

  摘要：

  DOI：

文献信息

• CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20180015087A1

  公开（公告）日：2018-01-18

  Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.

  提供了与谷氨酰脑结合化合物和具有调节活性对抗G12C突变KRAS、HRAS或NRAS G12C蛋白的化合物的共轭物。还提供了与制备和使用这种共轭物相关的方法，包括含有这种共轭物的药物组合物以及调节G12C突变KRAS、HRAS或NRAS G12C蛋白活性的方法，用于治疗癌症等疾病。
• Rodenticidal
  申请人：May & Baker Ltd.

  公开号：US04347252A1

  公开（公告）日：1982-08-31

  The hitherto unknown phenylpropargylamine derivative 1-(3,5-bistrifluoromethylphenyl)-3-(4-tert-butylpiperidino)prop-1-yne, and acid addition salts thereof, have been found to be useful for killing warm-blooded vermin, especially rodents. Processes for the preparation of the new phenylpropargylamine derivative are described and so are suitable rodenticidal compositions.

  迄今为止未知的苯基丙炔胺衍生物1-(3,5-双三氟甲基苯基)-3-(4-叔丁基哌啶基)丙-1-炔及其酸盐被发现可用于杀死温血动物害虫，特别是啮齿动物。描述了制备新苯基丙炔胺衍生物的过程以及适用的杀鼠剂组合物。
• A new phenylpropargylamine derivative
  申请人：MAY & BAKER LIMITED

  公开号：EP0041324A1

  公开（公告）日：1981-12-09

  The hitherto unknown phenylpropargylamine derivative 1-(3,5-bistrifluoromethylphenyl)-3-(4-tert-butyl- piperidino)prop-I-yne, and acid addition salts thereof, have been found to be useful as rodenticides. Processes for the preparation of the new phenylpropargylamine derivative by the application of known methods are described and so are suitable rodenticidal compositions.

  迄今未知的苯基丙炔基胺衍生物 1-(3,5-二氟甲基苯基)-3-(4-叔丁基-哌啶基)丙-I-炔及其酸加成盐已被发现可用作杀鼠剂。本文介绍了应用已知方法制备新的苯基丙炔基胺衍生物的工艺，并介绍了合适的杀鼠剂组合物。
• SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20160297774A1

  公开（公告）日：2016-10-13

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R 1 , R 2a , R 2b , R 2c , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6 , A, B, G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
• 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20170197945A1

  公开（公告）日：2017-07-13

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R 1 , R 2a , R 2b , R 2c , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6 , A, G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , n, X and E are as defined herein and, wherein at least one of R 3a , R 3b , R 4a or R 4b is not H. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.